{ banner }

Contraception Research

Since its founding in 1986, CONRAD has been internationally renowned for its leadership in developing new, safe and affordable contraceptive products. CONRAD continues building on its past efforts as it links basic and clinical research and brings investigators in the laboratory and the clinic together, whether they are in government agencies, nongovernmental organizations, foundations or the private sector. Through these efforts, reproduction is becoming more of a choice for millions of families in developing countries.

Male Contraceptives: Limiting male contraception to vasectomies and condoms, as is the case today, is very restrictive. CONRAD has supported investigators who are aggressively researching different compounds that can disrupt sperm production and function, so that safe, effective and inexpensive contraceptives can be offered to men. In collaboration with the World Health Organization (WHO), CONRAD is completing a clinical trial of a long-acting injectable hormonal contraceptive for men in several countries. Enrollment has ended and all men are in the Recovery Phase.

Female Contraceptives: While women have more contraceptive options than men, the high number of unplanned pregnancies throughout the world points to the need for additional contraceptive options. To address this need, CONRAD researchers are investigating novel leads for new hormonal and non-hormonal contraceptives and testing new contraceptive methods in the clinic. 

To learn more about CONRAD's male and female contraceptive preclinical activities, click here.

To learn more about CONRAD's male and female contraceptive clinical activities, click here.

Multipurpose Prevention Technologies: The ability to use a single product or application to prevent unplanned pregnancy and sexually transmitted infections (STIs), including HIV, would provide women with a simplified, more acceptable, and potentially less expensive choice for protection. To this end, CONRAD is developing contraceptive/anti-HIV technologies, including a 3-month intravaginal ring that will release both levonorgestrel (for pregnancy prevention) and tenofovir (for HIV prevention). Learn more about multipurpose prevention technologies in development here.

1911 North Fort Myer Drive, Suite 900, Arlington, VA 22209   T: 703.524.4744 |